For the second quarter of 2026, analysts expect Spero Therapeutics to report a consensus revenue of $0.28 million and a net loss of $0.17 per share, with the stock currently trading near $1.26 against a consensus price target of $4.00.
Investors are primarily focused on management's outlook for Utebzi (tebipenem HBr) royalties and milestones following its FDA approval in June 2026 for complicated urinary tract infections.
Spero has recently pivoted its strategy toward immunology, leveraging a $1.1 billion deal for lead asset SP001 and a $105 million royalty financing agreement with HealthCare Royalty Partners. This report will be the first since the company's major pipeline reprioritization and the commercial launch of Utebzi by partner GSK.